China Nuokang Bio-Pharmaceutical Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis

Date: October 15, 2018
Pages: 50
US$ 499.00
China Nuokang Bio-Pharmaceutical Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

China Nuokang Bio-Pharmaceutical Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis
China Nuokang Bio-Pharmaceutical Inc. Due Diligence Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between China Nuokang Bio-Pharmaceutical Inc. and its competitors. This provides our Clients with a clear understanding of China Nuokang Bio-Pharmaceutical Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about China Nuokang Bio-Pharmaceutical Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for China Nuokang Bio-Pharmaceutical Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The China Nuokang Bio-Pharmaceutical Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes China Nuokang Bio-Pharmaceutical Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of China Nuokang Bio-Pharmaceutical Inc. business.

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc., a biopharmaceutical company, focuses on the research, development, manufacture, marketing, and sales of hematological and cardiovascular products.

The company sells a portfolio of 14 products, including three principal products: Baquting, its bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent.

The company also has entered into an agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. The company’s product pipeline includes four product candidates under development to address the market and medical needs for bleeding control and hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.

In December 2008, the company entered into a 10-year distribution agreement with Jilin Yuhua to market and distribute Kaitong in China with the exception of Jilin and Heilongjiang Provinces.

The company’s product pipeline consists of four product candidates at various stages of development: dipyridamole aspirin sustained release capsules, which combines the anti-clotting or blood thinning properties of aspirin with the antiparticle and thrombus formation inhibition properties of dipyridamole, for the prevention of secondary strokes; hemocoagulase derived from the venom of the snake species Agkistrodon acutus for bleeding control; adenosine for myocardial protection; and lanthanum polystyrene sulfonate for the treatment of hyperphosphatemia, or high levels of blood phosphate typically found in chronic renal failure patients undergoing dialysis.

Other Products

The company also manufactures and sells the following 11 medicines: Salbutamol Aerosol, Erythromycin Ethylsuccinate Tablets, Metformin Hydrochloride Tablets, Ribavirin Spray, ‘Kanglai Baby’ Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Granules, Isoprenaline Hydrochloride Aerosol, Asarone for Injection, Clemastine Fumarate Tablets, Gavlacon Tablets, Lidocaine and Chlorhexine Acetate Aerosol, and Shengxue Tablets.

International Collaboration

In July 2009, the company entered into a joint venture with QRxPharma Limited, a publicly listed biopharmaceutical company in Australia.


The company’s end-customer base was approximately 2,400 hospitals in all 31 provinces and municipalities in China as of March 31, 2010. Its customers include Liaoning Pacific Medicine Co., Ltd.; Beijing Xidan Medicine Co., Ltd.; Chongqing Medicine Co., Ltd.; Beijing Aixin Weiye Medicine Co., Ltd.; and Sinopharm Group Co., Ltd.


The company’s main product Baquting competes primarily with Solco Basle’s Reptilase, Aohong Pharma’s Bangting and Lee’s Pharm’s Sulejuan. Kaitong would primarily compete with Beijing Tide Pharma’s Kaishi, Hayao Bio’s Manxintuo and Leilong Pharma’s Beichang.


China Nuokang Bio-Pharmaceutical Inc. was founded in 1997.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. China Nuokang Bio-Pharmaceutical Inc. Direct Competitors
5.2. Comparison of China Nuokang Bio-Pharmaceutical Inc. and Direct Competitors Financial Ratios
5.3. Comparison of China Nuokang Bio-Pharmaceutical Inc. and Direct Competitors Stock Charts
5.4. China Nuokang Bio-Pharmaceutical Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. China Nuokang Bio-Pharmaceutical Inc. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





China Nuokang Bio-Pharmaceutical Inc. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
China Nuokang Bio-Pharmaceutical Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
China Nuokang Bio-Pharmaceutical Inc. Major Shareholders
China Nuokang Bio-Pharmaceutical Inc. History
China Nuokang Bio-Pharmaceutical Inc. Products
Revenues by Segment
Revenues by Region
China Nuokang Bio-Pharmaceutical Inc. Offices and Representations
China Nuokang Bio-Pharmaceutical Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
China Nuokang Bio-Pharmaceutical Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
China Nuokang Bio-Pharmaceutical Inc. Capital Market Snapshot
China Nuokang Bio-Pharmaceutical Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
China Nuokang Bio-Pharmaceutical Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
China Nuokang Bio-Pharmaceutical Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


China Nuokang Bio-Pharmaceutical Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
China Nuokang Bio-Pharmaceutical Inc. 1-year Stock Charts
China Nuokang Bio-Pharmaceutical Inc. 5-year Stock Charts
China Nuokang Bio-Pharmaceutical Inc. vs. Main Indexes 1-year Stock Chart
China Nuokang Bio-Pharmaceutical Inc. vs. Direct Competitors 1-year Stock Charts
China Nuokang Bio-Pharmaceutical Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

China Nuokang Bio-Pharmaceutical Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: